Food and Drug Administration Accelerated Approval of Lecanemab for Early Alzheimer's Disease-Hope, Reality, and the Unknown Going Forward

被引：0
作者：
O'Malley, Patricia Anne [1 ,2 ]
机构：
[1] Premier Hlth Miami Valley Hosp, Dayton, OH USA
[2] Premier Hlth Nursing Res, 1 Wyoming St, Dayton, OH 45409 USA
来源：
CLINICAL NURSE SPECIALIST | 2023年 / 37卷 / 03期
关键词：
D O I：
10.1097/NUR.0000000000000745
中图分类号：
R47 [护理学];
学科分类号：
1011 ;
摘要：
[No abstract available]
引用
收藏
页码：111 / 113
页数：3
相关论文
共 15 条
[1]  
[Anonymous], 2022, LANCET, V400, P1899, DOI 10.1016/S0140-6736(22)02480-1
[2]  
Cavazzoni P, FDA's decision to approve new treatment for alzheimer's disease|FDA
[3]   Alzheimer's disease drug development pipeline: 2022 [J].
Cummings, Jeffrey ;
Lee, Garam ;
Nahed, Pouyan ;
Kambar, Mina Esmail Zadeh Nojoo ;
Zhong, Kate ;
Fonseca, Jorge ;
Taghva, Kazem .
ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 2022, 8 (01)
[4]   Critical Appraisal of Amyloid Lowering Agents in AD [J].
Decourt, Boris ;
Boumelhem, Fadel ;
Pope, Evans D., III ;
Shi, Jiong ;
Mari, Zoltan ;
Sabbagh, Marwan Noel .
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2021, 21 (08)
[5]  
Drugs @ FDA-Approved Drugs, BIOL LIC APPL BLA
[6]   Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease [J].
Johannesson, Malin ;
Sahlin, Charlotte ;
Soderberg, Linda ;
Basun, Hans ;
Falting, Johanna ;
Moller, Christer ;
Zachrisson, Olof ;
Sunnemark, Dan ;
Svensson, Anne ;
Odergren, Tomas ;
Lannfelt, Lars .
MOLECULAR AND CELLULAR NEUROSCIENCE, 2021, 114
[7]   Genomics of Alzheimer's disease implicates the innate and adaptive immune systems [J].
Li, Yihan ;
Laws, Simon M. ;
Miles, Luke A. ;
Wiley, James S. ;
Huang, Xin ;
Masters, Colin L. ;
Gu, Ben J. .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2021, 78 (23) :7397-7426
[8]   Is Alzheimer's Disease Risk Modifiable? [J].
Serrano-Pozo, Alberto ;
Growdon, John H. .
JOURNAL OF ALZHEIMERS DISEASE, 2019, 67 (03) :795-819
[9]   Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer's Disease: A Focus on Aducanumab and Lecanemab [J].
Shi, Mingchao ;
Chu, Fengna ;
Zhu, Feiqi ;
Zhu, Jie .
FRONTIERS IN AGING NEUROSCIENCE, 2022, 14
[10]  
U.S. Food & Drug Administration, 2021, FDA NEWS REL FDA GRA
12